There is no near-term relief in sight for generics makers, with erosion in the double digits to be expected next year. The key to overcoming a weak market? Complex generics and biosimilars, for those who have them, but even there success is not guaranteed. That, at least, is the view of Novartis exec Peter Goldschmidt, president of Sandoz US and head of North America for the Swiss drugmaker.
More: Sandoz head sees biosimilars as the light in the generics storm